Community/Retail

Pharmacy Times® and Parata Systems named the winners of the 2018 Next-Generation Pharmacist® Awards yesterday at a ceremony held concurrently with the 2018 NCPA Annual Meeting in Boston, Massachusetts.

The FDA has approved Akcea Therapeutics' inotersen (Tegsedi), an antisense oligonucleotide that inhibits the production of the transthyretin protein (amyloid), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

HR 6—which was passed in the Senate on Wednesday and in the House of Representatives last week—instructs the Secretary of Health and Human Services to establish a technical expert panel to review quality measures regarding opioids and opioid use disorders.

The Qualified Business Income Deduction proposed rule would expand the "specified service trade or business," or SSTB, definition of "services performed in the field of health" to include pharmacists.

This event continues through tomorrow until the start of the National Community Pharmacy Association’s annual meeting.

Although their use is sometimes necessary, overprescribing the bacteria-killing drugs can be dangerous.

The Pharmacy Quality Alliance has praised the bipartisan efforts of Congress in passing the SUPPORT for Patients and Communities Act (HR 6).

A program that provides pre-exposure prophylaxis to those at high risk of the infection is feasible and could help lower incidences, according to a study being presented at ID Week.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) for routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors.

The FDA has approved sarecycline (Seysara, Almirall) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.

The CDC suggests that providers can better inform women about the recommended maternal vaccines.

Given the knowledge that a single pharmacy position can attract hundreds of applications, you must do everything possible to keep yourself in contention.

The American Society of Health-System Pharmacists (ASHP) has published guidelines with practical recommendations and best practices for preventing patient harm from medication errors.

A recent survey concluded that strategies to increase workplace immunization, such as requiring vaccination or promoting free onsite vaccines, lead to increased vaccination rates.

The Drug Enforcement Administration is placing Epidiolex in Schedule V, the least restrictive of the Controlled Substances Act

Two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack are being voluntarily recalled by Endo Pharmaceuticals Inc., due to incorrent dosing information on the label.

Metabolic syndrome involves multiple disease states including hypertension, hyperlipidemia, and possibly diabetes.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Celebrating the expanded role of pharmacists across the nation, McKesson Corporation has kicked off an entire month of celebrations for American Pharmacists Month.

Officials with the FDA have approved Admais’ 0.15mg Symjepi for the emergency treatment of allergic reactions, including anaphylaxis, in children.

A global survey found that 2 of 3 individuals with type 2 diabetes had experienced a cardiovascular disease (CVD) event or had CVD risk factors.

The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria in a limited population of patients with the disease who do not respond to conventional treatment.

Officials with the FDA have approved cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA®, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

Get involved this October and show your appreciation for the work pharmacists do.

Dacomitinib tablets (Vizimpro, Pfizer) received FDA approval for the first-line treatment of patients with metastatic non-small cell lung cancer.

The FDA has approved Eli Lilly’s preventive migraine treatment galcanezumab-gnlm (Emgality).